Associate Professor
Biostatistics, Pharmacoeconomics and Outcomes Research
Joint appointments: Department of Medical Informatics and Clinical Epidemiology & Department of Public Health and Preventive Medicine at Oregon Health & Science University School of Medicine
Department of Pharmacy Practice
College of Pharmacy
Oregon Health & Science University
3303 SW Bond Ave., CH12C
Portland, OR 97239
Phone: 503-494-2258
Fax: 503-494-8797
kraemerd@ohsu.edu
Ph.D. in Biostatistics, University of Iowa, 1988
M.S. in Applied Statistics, Purdue University, 1977
M.S. in Ecology and Evolution, Purdue University, 1977
Dale Kraemer's research interests include economic evaluations of pharmaceutical and other therapies, assessing practice patterns and subsequent outcomes, medication reconciliation and use of large databases (such as medical claims databases) to develop and test hypotheses about occurrence of disease and treatment patterns. Clinical areas include oncology (brain tumors and chemoprotective agents), cardiology, diabetes, neurology, osteoporosis and women's health.
Raitt M, Connor W, Morris C, Kron J, Halperin B, Chugh S, McClelland J, Cook J, MacMurdy K, Swenson R, Connor S, Gerhard G, Kraemer DF, Oseran D, Marchant C, Calhoun D, Snyder R, McAnulty J. The Effect of Fish Oil Supplementation on the Risk of Ventricular Tachycardia and Ventricular Fibrillation in Patients with Implantable Defibrillators. Journal of the American Medical Association. 2005;293:2884-91.
Kraemer DF, Berlin M, Guise J-M. Associations of health care system characteristics with decision on mode of delivery in women with prior cesarean delivery: a systematic review. Women's Health Issues. 2004;14(3):94-103.
Neuwelt EA, Pagel MA, Kraemer DF, Peterson DR, Muldoon LL. Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. Journal of Pharmacology & Experimental Therapeutics. 2004;309(2):594-529.
Neuwelt EA, Pagel MA, Kraemer DF, Peterson DR, Muldoon LL. Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. Journal of Pharmacology & Experimental Therapeutics. 2004;309(2):594-529.
Kraemer DF. Fortin D. Neuwelt EA. Chemotherapeutic dose intensification for treatment of malignant brain tumors: recent developments and future directions. Current Neurology & Neuroscience Reports. 2002;2:216-24.
Kraemer DF. Fortin D. Neuwelt EA. Chemotherapeutic dose intensification for treatment of malignant brain tumors: recent developments and future directions. Current Neurology & Neuroscience Reports. 2002;2:216-24.
Kraemer DF, Fortin D, Doolittle ND, Neuwelt EA. Association of total dose intensity of chemotherapy in primary CNS lymphoma (human non-AIDS) and survival. Neurosurgery. 2001;48:1033-1040.
Russell MW, Huse DM, Miller JD, Kraemer DF, Hartz SC. Cost-effectiveness of HMG-CoA reductase inhibition in Canada. Canadian Journal of Clinical Pharmacology. 2001;8:9-16.
Ganzini L, Nelson HD, Kraemer DF, Delorit MA, Lee MA, Schmidt TA. Oregon physicians' Attitudes and experiences around end-of-life care since passage of the Oregon Death with Dignity Act. Journal of the American Medical Association. 2001;285:2363-2369.
Doolittle ND, Muldoon LL, Brummett RE, Tyson RM, Lacy C, Bubalo JS, Kraemer DF, Heinrich MC, Henry JA, Neuwelt EA. Delayed Sodium Thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clinical Cancer Research. 2001;7:493-500.
Doolittle ND, Muldoon LL, Brummett RE, Tyson RM, Lacy C, Bubalo JS, Kraemer DF, Heinrich MC, Henry JA, Neuwelt EA. Delayed Sodium Thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clinical Cancer Research. 2001;7:493-500.
Ganzini L, Nelson HD, Lee MA, Kraemer DF, Schmidt TA, Delorit MA. Oregon physicians' attitudes about and experiences with end-of-life care since passage of the Oregon Death with Dignity Act. Journal of the American Medical Association. 2001;285:2363-9.
Ganzini L, Nelson HD, Schmidt TA, Kraemer DF, Delorit MA, Lee MA. Physicians' experiences with the Oregon Death with Dignity Act. New England Journal of Medicine. 2000;342:557-63.
Doolittle ND, Miner ME, Hall WA, Siegal T, Osztie E, McAllister LD, Bubalo JS, Kraemer DF, Fortin D, Nixon R, Muldoon LL, Neuwelt, EA. Safety and efficacy of a multicenter study of using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer. 2000;88:637-647.
McAllister LD, Doolittle ND, Guastadisengi PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery. 2000;46:51-60.
Huse DH, Russell MW, Miller JD, Kraemer DF, D'Agostino RB, Ellison RC, Hartz SC. Cost-effectiveness of HMG-Co-A reductase inhibition: an update. American Journal of Cardiology. 1998;82:1357-1363.
Kraemer DF, Woolson RF. A Monte Carlo study to evaluate the performance of selected tests of homogeneity in sparse contingency tables. Biometrical Journal. 1988;30:763-778.
Kraemer DF, Woolson RF. A comparison of tests of homogeneity for sparse contingency tables. Communications in statistics–Simulation and computation. 1987;16:465-483.
